Claims for Patent: 7,871,819

Summary for Patent: 7,871,819

Title:	Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
Abstract:	The invention provides a recombinant vector comprising an ovine adenovirus genome and a sequence encoding a heterologous polypeptide, wherein the sequence encoding the heterologous polypeptide is inserted between E4 and E3 transcription units of the ovine adenovirus genome.
Inventor(s):	Molloy; Peter L. (New South Wales, AU), Watt; Fujiko (Rozelle, AU), Both; Gerry (New South Wales, AU)
Assignee:	Commonwealth Scientific and Industrial Research Organisation (Australian Capital Territory, AU)
Application Number:	11/311,637
Patent Claims:	1. A recombinant vector comprising an ovine adenovirus genome and a sequence encoding a heterologous polypeptide, wherein the sequence encoding the heterologous polypeptide is inserted between E4 and E3 transcription units of the ovine adenovirus genome, and wherein at least one enhancer element obtained from intron 3 of the PSM gene is operably linked to the sequence encoding the heterologous polypeptide. 2. A recombinant vector as claimed in claim 1, wherein the sequence encoding the heterologous polypeptide is inserted between nucleotides 26,682 and the 5' end of the E4 promoter of the ovine adenovirus genome. 3. A recombinant vector as claimed in claim 1, wherein the sequence encoding the heterologous polypeptide is inserted between nucleotides 26,682 and 26,555 of the ovine adenovirus genome. 4. A recombinant vector as claimed in claim 1, wherein the sequence encoding the heterologous polypeptide is inserted between an Apa1 and Not1 site between the E4 and E3 transcription units of the ovine adenovirus genome. 5. A recombinant vector as claimed in claim 1, wherein the vector comprises a heterologous promoter. 6. A recombinant vector as claimed in claim 5, wherein the promoter is located upstream from and is operably linked to the sequence encoding the heterologous polypeptide. 7. A recombinant vector as claimed in claim 5, wherein the vector comprises at least one regulatory element obtained from intron 3 of the PSM gene operably linked to the heterologous promoter. 8. The recombinant vector of claim 1 wherein the ovine adenovirus vector has increased stability. 9. A recombinant vector according to claim 1 in which the enhancer element comprises nucleotides 1-171 of SEQ ID NO: 1. 10. A recombinant vector according to claim 1 in which the enhancer element comprises nucleotides 1-332 of SEQ ID NO: 1. 11. A method for directing expression of a coding sequence in a cell, the method comprising introducing into the cell a recombinant vector according to any one of claims 1-4, 5 and 6. 12. A method of delivering a sequence encoding a heterologous polypeptide to a target cell, the method comprising transducing the cell with a recombinant vector according to any one of claims 1-4, 5 and 6. 13. A method of delivering a sequence encoding a heterologous polypeptide to an animal cell, the method comprising administering to an animal or a cultured animal cell a recombinant vector according to any one of claims 1-4, 5 and 6. 14. A method of gene transfer to human cells, the method comprising administering to the cells a recombinant vector according to any one of claims 1-4, 5 and 6 such that the vector infects at least one cell and the infected cell expresses the heterologous polypeptide.

Details for Patent 7,871,819

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-03-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-03-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-03-01